Anti-Beta2-Glycoprotein 1 IgM ELISA Kit
Anti-Beta2-Glycoprotein-1 IgM ELISA Kit Developed and Manufactured by Svar Life Science
Size: 1×96 wells
Sensitivity: See Package Insert
Dynamic Range: Cut-off
Incubation Time: 2 hours
Sample Type: Serum, Plasma
Sample Size: 10 µL
For Research Use Only
Sample Collection and Storage:
The Anti-Beta2-Glycoprotein-1 IgM ELISA Kit is recommended for serum/plasma (sodium citrate, EDTA (K2), lithium heparin anticoagulated) samples; do not use lipaemic, haemolysed, icteric or turbid samples. Thoroughly mix thawed samples before assay and avoid repeated freeze/thawing. Do not heat-inactivate samples, this may yield false positive results. Samples may be stored at 1:101 dilution in diluted Sample Diluent 2 for up to 24 hours at 2-8° C, or up to 9 hours at +20° C. For longer storage, store undiluted samples at –20° C.
β2-glycoprotein 1 (β2GP1), or apolipoprotein H, is a plasma glycoprotein that circulates at approximately 200μg/ml. It is associated with plasma lipoproteins, in particular very low-density lipoprotein, and may regulate haemostatic actions occurring on the lipoprotein surface. β2GP1 has been shown to inhibit the intrinsic coagulation pathway via inhibition of Factor XII activation on negatively charged surfaces, and is the dominant antigen for antiphospholipid antibodies (APAs) in patients with anti-phospholipid syndrome.
The presence of APAs such as anti-cardiolipin antibodies is associated with venous and arterial thrombosis, recurrent spontaneous abortions and thrombocytopenia. Anti-cardiolipin antibodies are also present in response to a variety of infections and certain drug treatments. APAs associated with infections are usually transient and not associated with thromboembolic complications; APAs in autoimmune disease are often associated with thromboembolic disease.
Although the mechanism of APA binding is poorly understood, it has been demonstrated that APAs may bind directly to phospholipid or via a protein co-factor, most commonly β2GP1. β2GP1 is often included in anti-cardiolipin assays to ensure the detection of both β2GP1-dependent and β2GP1-independent antibodies. β2GP1-dependent APAs tend to be associated with autoimmune disease; β2GP1-independent APAs tend to be associated with infection. A number of studies have demonstrated that detection of β2GP1 antibodies, in conjunction with anticardiolipin measurement, is important in defining the thrombotic risk associated with APAs.